UT Health San Antonio examines infectious diseases of regional and national significance, including hepatitis, HIV, multidrug resistant bacteria, clostridium difficile and MRSA infections.
Infectious disease expert Sunil Ahuja, M.D. earned the prestigious MERIT Award an honor bestowed on less than five percent of NIH-funded researchers.
Our research in antifungal therapies is nationally and internationally renowned.
UT Health San Antonio conducts research on infectious diseases at clinical settings throughout our partnership network, including Texas Center for Infectious Diseases, South Texas Veterans Health Care System and University Health System.
UT Health San Antonio is leading a clinical research program focused on new therapies for HIV and metabolic disorders associated in patients with HIV.
While acknowledging that improvements in therapies have led to better care of patients with invasive aspergillosis - a potentially deadly fungal infection - new practice guidelines emphasize that there remains a critical need for early diagnosis.
Scientists at UT Health San Antonio have discovered why oxamniquine, a drug used to treat a global infection called schistosomiasis, is only effective against one species of the parasitic flatworm and not two others.
Just a few years ago the outlook for treating patients with chronic hepatitis C was grim. For almost a year, patients would receive a complicated regimen of shots and up to 18 pills a day with drugs that caused major side effects. After that, there was a six-month follow-up period to see if the treatment was successful. And the cure rate was less than 50 percent.
Patients with life-threatening fungal infections have new hope for survival and less-severe side effects with the U.S. Food and Drug Administration’s approval of a new drug, isavuconazonium sulfate, also called CRESEMBA®.